Abstract 868P
Background
Many patients with oral (OSCC) and oropharyngeal squamous cell carcinoma (OPSCC) experience disease recurrence after surgery with curative intent despite R0 resection and adjuvant treatment. Several methods, including frozen section analysis, are available to evaluate surgical margins. However, precancerous epigenetic disturbances may predate morphological changes. This study aimed to address the unmet need for intraoperative recurrence prediction based on molecular features in clear resection margins.
Methods
Infinium EPIC BeadChip 850k methylation analysis of 71 OPSCC primary tumors (TU), 16 contralateral healthy mucosa (HM), and 70 resection margins (RM: OPSCC & OSCC) was conducted. Oncogenic features were selected based on TU vs. HM differential methylation analysis (Kruskal Wallis Tests: η2 > 0.14 and FDR < 0.05). Baseline classifiers were trained, and the best-performing classifier was optimized by hyperparameter tuning and feature selection, allowing the integration of 46 TCGA R0 margin (normal adjacent tissue) data. Features selected were checked for common single nucleotide polymorphisms (SNP), and correlation analysis between loci methylation and gene expression (RNAseq) was conducted. Four margin samples analyzed with Epic BeadChip were also sequenced with Oxford Nanopore Technology (ONT) Mk1C.
Results
Forty-nine thousand features were selected to train six baseline classifiers, and XGBoost was chosen. XGBoost training with 10-fold cross-validation, hyperparameter tuning, and seven features (hypomethylated in TU compared to HM) selection led to the construction of a classifier model that predicts recurrence with a mean area under the ROC curve (AUC) of 0.80 (95% CI = 0.73 - 0.87). None of the seven loci used in constructing the model harbored a common SNP (MAF < 0.01). A significant correlation between the methylation level of five of the CpG loci and RNA expression was discovered (p < 0.05). ONT methylation output exhibited a strong positive correlation with Epic BeadChip for all the intersected loci (r = 0.83, p < 0.001), but most importantly, the seven selected features (r = 0.90, p < 0.001).
Conclusions
Disease recurrence can be predicted from morphologically clear surgical margins using a methylation classifier.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Research Training Group GRK-2254 (HEIST, 288342734) funded by Deutsche Forschungsgemeinschaft (DFG).
Disclosure
S. Laban: Other, Institutional, Advisory Board: Merck Sharp & Dohme, Bristol Myers Squibb, Sanofi Genzyme; Financial Interests, Institutional, Advisory Board, Travel reimbursement: AstraZeneca ; Financial Interests, Institutional, Other, Travel reimbursement: Merck Serono. All other authors have declared no conflicts of interest.
Resources from the same session
890P - Real-world survival outcomes and survival risk factors in elderly patients with locally advanced squamous cell carcinoma of the head and neck
Presenter: Nabil Saba
Session: Poster session 12
891P - Changing landscape of head and neck squamous cell carcinoma (HNSCC) treatment and survival in Thailand: A 13-year multicenter retrospective study of 6,319 patients
Presenter: Nuttapong Ngamphaiboon
Session: Poster session 12
892P - Real-world data validation of university of San Diego nomogram for the prediction of benefit of intensive treatment for locoregionally advanced head and neck cancer
Presenter: Javier Caballero Daroqui
Session: Poster session 12
893P - Tumor node stage shift following leukocyte interleukin injection neoadjuvant extends overall survival in treatment-naïve locally advanced oral cavity/soft palate squamous cell carcinoma
Presenter: Jozsef Timar
Session: Poster session 12
894P - Is pathological complete response (PCR) a surrogate endpoint of overall survival in patients with technically unresectable oral cavity cancers? A real-world data study of 900 plus patients
Presenter: Shatabdi Chakraborty
Session: Poster session 12
896P - Efficacy and safety of pembrolizumab with preoperative neoadjuvant chemotherapy in patients with resectable locally advanced head and neck squamous cell carcinomas
Presenter: Kai Wang
Session: Poster session 12
897P - Nanosomal docetaxel lipid suspension (NDLS) or docetaxel based neoadjuvant therapy in Head and neck squamous cell carcinoma: Post hoc analysis of a prospective, randomized study
Presenter: Darshit Shah
Session: Poster session 12
898P - Meta-analysis of two placebo-controlled trials of avasopasem manganese (AVA) in patients with locally advanced, head & neck cancer (LAHNC)
Presenter: Neal Dunlap
Session: Poster session 12
899P - Impact of COVID-19 pandemic on treatment and survival in head and neck squamous cell carcinoma (HNSCC) patients (IMPACCT Study)
Presenter: Berta Vilar Anglada
Session: Poster session 12